PanOptica: PanOptica Doses First Patient with New Formulation of PAN90806 a Novel Topical AntiVEGF Eye Drop in Phase 12 Clinical Trial

Nextgeneration Suspension Formulation Designed to Improve Tolerability and Treatment Response in Patients with Wet AMD IND Amendment in US and CTAs Filed in EU for Phase 12 Trial PanOptica Inc. a private biopharmaceu...